<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139420</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00039217</org_study_id>
    <nct_id>NCT05139420</nct_id>
  </id_info>
  <brief_title>Risk of Metabolic Adaptation After Weight Loss</brief_title>
  <official_title>Biomarkers of Increased Risk of Developing Metabolic Adaptation to Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at identifying the neurohormonal biomarkers that characterize individuals at&#xD;
      risk of greater metabolic adaptation to weight loss, a disproportionate decline in resting&#xD;
      metabolic rate during and after weight loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in measured and predicted resting metabolic rate during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>resting metabolic rate will be measured by indirect calorimetry every 2 months for 6 months, then every 6 months for an additional 12 month. Predicted resting metabolic rate will be calculated with a mathematical formula at the same time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in circulating leptin during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in circulating thyroid hormones during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in circulating GLP-1 during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in circulating PYY during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in circulating AgRP during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in 24h urine catecholamines during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>urine will be assayed for these hormones every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in heart rate variability during and after weight loss</measure>
    <time_frame>18 months</time_frame>
    <description>blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Weight Loss</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>lifestyle intervention plus phentermine-topiramate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phentermine-topiramate combined with lifestyle intervention</intervention_name>
    <description>participants will be enrolled in a medical weight loss program and will be prescribed phentermine-topiramate to help with weight loss. The goal of the study is NOT to assess efficacy or safety of this drug</description>
    <arm_group_label>lifestyle intervention plus phentermine-topiramate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        BMI &gt; or = 30 any ethnicity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        weight &gt; or = 400 lbs.&#xD;
&#xD;
        diabetes (type 2 or type 1)&#xD;
&#xD;
        hypertension&#xD;
&#xD;
        heart disease&#xD;
&#xD;
        kidney disease&#xD;
&#xD;
        liver disease&#xD;
&#xD;
        active cancer&#xD;
&#xD;
        post solid organ or bone marrow transplant&#xD;
&#xD;
        HIV/AIDS&#xD;
&#xD;
        pregnancy&#xD;
&#xD;
        breastfeeding&#xD;
&#xD;
        current smoker&#xD;
&#xD;
        current recreational drug use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa L Morselli, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa L Morselli, MD PhD</last_name>
    <phone>414-955-6710</phone>
    <email>lmorselli@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland James</last_name>
    <phone>414-955-4992</phone>
    <email>rjames@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Roland James</last_name>
      <phone>414-955-4992</phone>
      <email>rjames@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa L Morselli, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Srividya Kidambi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Lisa Morselli, MD PhD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>resting metabolic rate</keyword>
  <keyword>metabolic adaptation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

